PRAC starts review of safety of injectable iron-containing medicines

• September 8, 2026
• Pharmacovigilance
• Safety Announcements
• 08 Sep 2026

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting, 6 – 9 July 2026

• 15 July 2026
• Pharmacovigilance
• Safety Announcements
• 15 Jul 2026

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting, 8 – 11 June 2026

• June 18 2026
• Safety Announcements
• Pharmacovigilance
• June 18, 2026

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting, 7 – 10 April 2026

• April 17 2026
• Safety Announcements
• Pharmacovigilance
• 17 Apr 2026

Arixtra (fondaparinux sodium) – Serious quality defect related to the needle in a pre-filled syringe – Direct communication to healthcare professionals

• February 24 2026
• Health professionals
• Announcements
• Safety Announcements
• 24 Feb 2026

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting, 27 – 30 October 2025

• 7 November 2025
• Pharmacovigilance
• Safety Announcements
• 07 Nov 2025

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting, 1 – 4 September 2025

• September 9, 2025
• Safety Announcements
• Pharmacovigilance
• 09 Sep 2025

Illegal drugs in the GLP-1 agonist class

• September 5, 2025
• Citizens
• Medicines
• Health professionals
• Uncategorized
• Manufacturing
• Organization announcements
• Safety Announcements
• Announcements
• Announcements
• 05 Sep 2025

Rybelsus: Risk of medication error due to formulation change

• 6 August 2025
• Pharmacovigilance
• Safety Announcements
• 06 Aug 2025

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting, 7 – 10 July 2025

• 15 July 2025
• Pharmacovigilance
• Safety Announcements
• 15 Jul 2025